Skip to content

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Sep 2026

From laboratory to industry: Systematic approaches to the biomanufacturing of short-chain diols.

Short-chain diols (C2-C6) are key platform chemicals widely used in polyesters and polyurethanes; however, their large-scale adoption remains limited by cost, scalability, and process robustness. This review summarizes recent advances in microbial production from an integrated perspective encompassing chassis engineering, pathway engineering, and process optimization. We compare model and non-model hosts, highlighting trade-offs between genetic tractability and native metabolic capacity, and analyze biosynthetic pathways with respect to carbon efficiency, redox balance, and pathway compatibility. Strategies to enhance microbial cell factories including enzyme engineering, metabolic flux regulation, cofactor engineering, and adaptive laboratory evolution are discussed to improve titer, yield, and productivity. We further evaluate the shift toward low-cost and sustainable feedstocks, such as crude glycerol, lignocellulosic biomass, and C1 substrates. To bridge microbial production with industrial implementation, key industrial constraints, including oxygen transfer, feedstock variability, downstream separation and biosafety, are examined. A second-hydroxyl-forming-unit conservation rule is proposed and integrated with process-level evidence to assess structural, performance, and process transferability across diol pathways. Techno-economic analysis (TEA) and life-cycle assessment (LCA) are discussed as essential tools for evaluating industrial feasibility. Finally, the downstream value of short-chain diols beyond their conventional uses is discussed, with emphasis on emerging opportunities for bioconversion and catalytic upgrading into high-value chemicals and functional materials. These analyses provide an evidence-based framework for product-specific pathway and process decisions in short-chain diol biomanufacturing.

Shao-Lun Zhang, Wan-Qing Wei, Linpei Zhang et al. · 0 citations
Jul 2026

Metabolic flux reprogramming and protein engineering drive efficient l-arginine biosynthesis.

l-arginine is widely used in food, feed, pharmaceutical, and cosmetic industries. However, its industrial-scale biosynthesis is limited by insufficient coordination between metabolic regulation, pathway engineering, and fermentation optimization. In this study, an enzyme-constrained model (ec_iML1515) was used to identify 11 gene targets affecting l-arginine production. Based on these targets, metabolic reprogramming was performed in strain Arg4 to rebalance precursor pools (oxaloacetate, aspartate, and citrulline), generating strain Arg10 with an l-arginine titer of 87.24 g/L. Subsequently, the rate-limiting enzyme argininosuccinate synthetase (ArgG) was engineered to the optimal mutant ArgGY131F/K132R and genomically integrated to construct the strain Arg11, increasing the l-arginine titer to 94.80 g/L while reducing aspartate accumulation 7.6-fold to 1.1 g/L. Finally, after the optimization of fermentation temperature and pH, the l-arginine titer, yield, and productivity of strain Arg11 were 114.18 g/L, 0.57 g/g, and 2.27 g/L/h, respectively, in a 3-m3 fermenter, achieving the best performance reported to date.

Shengyang He, Qi Sheng, Gang Men et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.